Morphological Cell Profiling of SARS-CoV-2 Infection Identifies 1 Drug Repurposing Candidates for COVID-19
Autore: Carmen Mirabelli, Jesse W. Wotring, Charles J. Zhang, Sean M. McCarty, Reid Fursmidt, Tristan Frum, Namrata S. Kadambi, Anya T. Amin, Teresa R. O’Meara, Carla D. Pretto, Jason R. Spence, Jessie Huang, Konstantinos D. Alysandratos, Darrell N. Kotton, Samuel K. Handelman, Christiane E. Wobus, Kevin J. Weatherwax, George A. Mashour, Matthew J. O’Meara, and Jonathan Z. Sexton
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI. Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Department of Internal Medicine, Gastroenterology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, USA. U-M Center for Drug Repurposing, University of Michigan, Ann Arbor, MI, USA. Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, USA. Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA. The Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA, USA. Michigan Institute for Clinical and Health Research (MICHR), University of Michigan, Ann Arbor, MI, USA. College of Pharmacy, University of Michigan, Ann Arbor, MI, USA. Department of Anesthesiology, Michigan Medicine at the University of Michigan, Ann Arbor, MI, USA. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Morphological Cell Profiling of SARS-CoV-2 Infection Identifies 1 Drug Repurposing Candidates for COVID-19
